Scarica l'app Stockscreener
8.75
3.95%
-0.36
Dopo l'orario di chiusura:
8.75
Precedente Chiudi:
$9.11
Aprire:
$9.02
Volume 24 ore:
798.73K
Relative Volume:
1.72
Capitalizzazione di mercato:
$1.33B
Reddito:
$43.34M
Utile/perdita netta:
$-247.99M
Rapporto P/E:
-4.4331
EPS:
-1.9738
Flusso di cassa netto:
$-224.28M
1 W Prestazione:
-7.51%
1M Prestazione:
-9.98%
6M Prestazione:
-16.67%
1 anno Prestazione:
+50.60%
Intervallo 1D:
$8.655
$9.09
Intervallo di 1 settimana:
$8.655
$9.57
Portata 52W:
$5.67
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
8.75 | 1.39B | 43.34M | -247.99M | -224.28M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-05-28 | Iniziato | Deutsche Bank | Buy |
| 2024-10-07 | Iniziato | Piper Sandler | Overweight |
| 2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2020-11-20 | Iniziato | BofA Securities | Buy |
| 2020-09-22 | Iniziato | Goldman | Buy |
| 2020-07-27 | Iniziato | SVB Leerink | Outperform |
| 2020-07-24 | Iniziato | Jefferies | Buy |
Mostra tutto
Immatics N V Borsa (IMTX) Ultime notizie
Price-Driven Insight from (IMTX) for Rule-Based Strategy - Stock Traders Daily
Immatics N.V. (IMTX) Holds at $9.43 as Shares Consolidate Above Key SupportShort Term Trading Ideas - vinanet.vn
Immatics stock holds near USD 9.60 after market cap update - ad-hoc-news.de
Immatics N.V. Warrants (IMTXW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Immatics (NASDAQ:IMTX) Shares Up 5.3% on Insider Buying Activity - MarketBeat
Insider Buying: Immatics (NASDAQ:IMTX) Director Purchases 863,060 Shares of Stock - MarketBeat
Perceptive fund boosts Immatics (IMTX) stake with new open-market share buy - Stock Titan
Perceptive Advisors Acquires 863,060 Shares of Immatics N.V. at $8.69 Each - Kalkine Media
Trading Systems Reacting to (IMTX) Volatility - Stock Traders Daily
Immatics (NASDAQ: IMTX) raises fresh cash to fund oncology pipeline - Stock Titan
Form 424B2 Immatics N.V. - StreetInsider
Why is Immatics stock climbing today? By Investing.com - Investing.com India
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday - Sahm
Why Immatics (IMTX) Is Down 5.4% After Mixed First‑Half 2026 Loss Trends And What's Next - simplywall.st
Immatics N.V. (NASDAQ:IMTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
James Nelson Pepin Net Worth (2026) - GuruFocus
Immatics (NASDAQ:IMTX) Shares Down 8%Should You Sell? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Immatics Announces Second Quarter 2026 Financial Results and Business Update - Sahm
Immatics (IMTX) awards counsel Nelson 225K share package - Stock Titan
Immatics Releases Q2 2026 Financial Results - AlphaStreet
Immatics Q2 revenue rises to $10.4 million - grafa.com
Immatics earnings on deck as analysts eye revenue trajectory By Investing.com - Investing.com India
Immatics earnings on deck as analysts eye revenue trajectory - Investing.com
Immatics Q2 Results: EPS misses estimate, sales up 93% YoY - scanx.trade
IMTX Looks 176.9% Overvalued on GF Value™ - GuruFocus
Immatics (NASDAQ:IMTX) Issues Earnings Results - MarketBeat
Immatics (IMTX) Slides 2.01% as Shares Approach Key $8.79 Support LevelQuality Factor - Vinanet
Immatics Posts Interim Q2 2026 Results and Updates Investor Materials - TipRanks
Immatics' Q2 Net Loss Narrows as Revenue Rises - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q2 Revenue 9.1M Euros, vs. FactSet Est of 10.4M Euros - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.46 Euros a Share, vs. FactSet Est of 0.45 Euros Loss - marketscreener.com
Immatics reports Q2 EPS (46c), consensus (48c) - TipRanks
Immatics: Q2 Earnings Snapshot - marketscreener.com
Immatics (NASDAQ: IMTX) posts €120m loss funding Phase 3 melanoma push - Stock Titan
Immatics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Press Release: Immatics Announces Second Quarter 2026 Financial Results and Business Update - Moomoo
IMTX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Pipeline InvestmentEPS Surprise History - vinanet.vn
Immatics (IMTX) Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Preclinical and Clinical InvestmentConsensus Beat Rate - dars.gov.et
Immatics (IMTX): Baker Bros. group reports 9.5M-share, 7% ownership stake - Stock Titan
Genetically Reprogrammed T Cells Erase Terminal Kidney Cancer in Teen, NEJM Reports - Tech Times
Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immatics N.V. expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Immatics N.V. (IMTX) Stock Analysis: Unveiling An 89.67% Potential Upside For Investors - DirectorsTalk Interviews
IMTX Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D-Driven BurnDividend Cut Risk - vinanet.vn
How Immatics N.v. (IMTX) Affects Rotational Strategy Timing - Stock Traders Daily
Immatics (IMTX): Will Anzu-cel Take The PRAME Crown In Advanced Melanoma? - RTTNews
Immatics (IMTX) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Immatics (IMTX) Slips 5.9% to $8.66 as Biotech Selling Pressure IntensifiesIron Condor Alert - vinanet.vn
Immatics N.V. (IMTX) Stock Analysis: Exploring a 105% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
IMTX|Immatics NV|Price:9.425|Chg%:-0.165 - TradingKey
Immatics N V Azioni (IMTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):